Inotuzumab ozogamicin
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD22 |
| Clinical data | |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6518H10002N1738O2036S42 |
| Molar mass | 150,000 g/mol |
  (what is this?)
|
|
Inotuzumab ozogamicin (CMC-544) is an antibody-drug conjugate for the treatment of cancers. It consists of the humanized monoclonal antibody inotuzumab (for CD22), linked to a cytotoxic agent from the class of calicheamicins (which is reflected by '' in the drug's name).
This drug is being developed by Pfizer and UCB.
It has undergone numerous clinical trials, including two phase II trials for Non-Hodgkin lymphoma (NHL).
A Phase III trial in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who were not candidates for intensive high-dose chemotherapy was terminated for futility.
As of April 2016[update] ten clinical trials were active (including one phase III for Acute Lymphoblastic Leukemia (ALL)), six still recruiting.
...
Wikipedia